Clinical Trials
28 trialsV503-064
Merck Sharp & Dohme LLC
FUTURE II
Merck Sharp & Dohme LLC
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
A Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
V503-053
Merck Sharp & Dohme LLC
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Shanghai Zerun Biotechnology Co.,Ltd
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
ING-HPV-1
SPP Pharmaclon Ltd.
V503-017
Merck Sharp & Dohme LLC
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006)
Merck Sharp & Dohme LLC
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Merck Sharp & Dohme LLC
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
V501-020
Merck Sharp & Dohme LLC
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
FUTURE
Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Merck Sharp & Dohme LLC
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Merck Sharp & Dohme LLC
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents
Catalysis SL
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
MediGene